MSD calls off £1bn UK expansion amid government-big pharma tensions
Merck & Co (MSD) has ditched plans for its £1bn R&D centre in London, UK, while ceasing drug discovery and …
Merck & Co (MSD) has ditched plans for its £1bn R&D centre in London, UK, while ceasing drug discovery and …
The UK is at risk of losing its world-leading life sciences status due to investment being captured elsewhere on the …
Kriya Therapeutics has closed an oversubscribed Series D funding round, raising $320m, aimed at propelling its gene therapy pipeline targeting …
China’s National Medical Products Administration (NMPA) has approved Sanofi’s Tzield (teplizumab), making it the first disease-modifying therapy for autoimmune type …
The biopharmaceutical industry faces headwinds from the Trump administration’s ongoing tariffs and drug pricing pressures in the US. As a …
US President Donald Trump is launching an enforcement drive against pharmaceutical companies and social media influencers who are responsible for …
Capricor Therapeutics has publicised a statement addressing the US Food and Drug Administration’s (FDA) decision to reject its Duchenne muscular …
Novo Nordisk will cut 9,000 jobs as part of a savings plan as the drugmaker fails to grapple with the …
Kytopen, a provider of continuous flow cellular engineering technologies, has collaborated with BlueWhale Bio to advance the manufacturing process of …
Health Canada has approved Medison Pharma and Ipsen’s Bylvay (odevixibat) to treat cholestatic pruritus in patients aged 12 months and …
Swiss pharma giant Novartis has agreed to acquire clinical-stage biopharmaceutical company Tourmaline Bio for $1.4bn. Through this deal, Novartis will expand …
The US Government has ordered $56m worth of mpox/smallpox vaccines to bolster public health preparedness, despite wider uncertainty in the …
Novo Nordisk’s decision to significantly reduce the price of blockbuster drug semaglutide is expected to slow the shift of patients …
Eli Lilly is seeking a label expansion for earlier use of Jaypirca (pirtobrutinib) in treatment-naïve patients with chronic lymphocytic leukaemia …
Servier has agreed to acquire Medicxi company Kaerus Bioscience's potential Fragile X syndrome (FXS) treatment, KER-0193. Servier will pay Kaerus Bioscience …